Reneuron Share Discussion Threads

[deltar] 02/12/2013 18:57

RF....call the Samaritans before it's too late.

[rocket fuel] 02/12/2013 13:56

as predicted (it wasn't hard) just over £3m cash burn from end of march to end of sep for twiddling their thumbs and jetting off to global confrences on five star business class jollies. and of course just over another million pounds cash burnt since then to bring us right up to date.
that's c£4.5m burn for the last 8 months without a soul in clinic the whole time. so that leaves you with c£22.5m from today with the meter ticking. going like the clappers!
in my opinion cash burn will increase from the current £530k per month (no patients in clinic) to c£1m p/m (patients being treated) for 001 phase2 alone.
throw in 009 then 003 as well as OSIS, and not to mention extra burn going on isolating and purifying nanoparticles (don't know where that one came from all of a sudden) then i fancy they will be burning at a rate of nigh on £2m per month.
i will give this company till spring 2015 before they call in the administrators.

[dickbush] 02/12/2013 12:21

I'm surprised there hasn't been any comment on today's interim report. It's an exciting read.

[qpr67] 25/11/2013 22:33

Human neural stem cells could meet the clinical problem of critical limb ischemia

posted by news on november 25, 2013 - 3:00pm

New research has shown human neural stem cells could improve blood flow in critical limb ischemia through the growth of new vessels. Critical limb ischemia (CLI) is a disease that severely obstructs arteries and reduces the blood flow to legs and feet. CLI remains an unmet clinical problem and with an ageing population and the rise in type II diabetes, the incidence of CLI is expected to increase.

The study, led by academics in the University of Bristol's School of Clinical Sciences, is published online in the American Heart Association journal Arteriosclerosis, Thrombosis, and Vascular Biology.

Current stem cell therapy trials for the treatment of CLI have revitalised new hope for improving symptoms and prolonging life expectancy. However, there are limitations on the use of autologous cell therapy. The patient's own stem cells are generally invasively harvested from bone marrow or require purification from peripheral blood after cytokine stimulation. Other sources contain so few stem cells that ex vivo expansion through lengthy bespoke Good Manufacturing Practice processes is required. Ultimately, these approaches lead to cells of variable quality and potency that are affected by the patient's age and disease status and lead to inconsistent therapeutic outcomes.

In order to circumvent the problem a team, led by Professor Paolo Madeddu in the Bristol Heart Institute at the University of Bristol, has used a conditionally immortalised clonal human neural stem cell (hNSC) line to treat animal models with limb ischaemia and superimposed diabetes. The CTX cell line, established by stem cell company ReNeuron, is genetically modified to produce genetically and phenotypically stable cell banks.

Results of the new study have shown that CTX treatment effectively improves the recovery from ischaemia through the promotion of the growth of new vessels. The safety of CTX cell treatment is currently being assessed in disabled patients with stroke [PISCES trial, NCT01151124]. As a result, the same cell product is immediately available for starting dose ranging safety and efficacy studies in CLI patients.

Professor Paolo Madeddu, Chair of Experimental Cardiovascular Medicine and Head of Regenerative Medicine Section in the Bristol Heart Institute at the University of Bristol, said: "Currently, there are no effective drug interventions to treat CLI. The consequences are a very poor quality of life, possible major amputation and a life expectancy of less than one year from diagnosis in 50 per cent of all CLI patients.

"Our findings have shown a remarkable advancement towards more effective treatments for CLI and we have also demonstrated the importance of collaborations between universities and industry that can have a social and medical impact."

Dr John Sinden, Chief Scientific Officer of ReNeuron, added: "The novel idea of using neural stem cells to treat vascular disease arose from a chance discussion with Professor Madeddu. The discussion led to a short pilot study with our cells producing very clear data, which then developed into a further eight experiments exploring different variants of the disease model, the product formulation and dose variation.

"The study also explored the cascade of molecular events that produced vascular and muscle recovery. It is a great example of industry and academia working successfully towards the key goal, clinical translation."

Source: University of Bristol

[stewart_25] 20/11/2013 11:36

Thx Dr Fillip...

[dr fillip strange] 20/11/2013 11:32

current Bid 3.39 Offer 3.50 - TD Direct

[stewart_25] 20/11/2013 11:22

My LSE shows as 3.62 - can anyone else confirm? was just cr@pping myself ...

[bigspuds] 19/11/2013 21:44

Clearing the decks per results

[daytraders] 19/11/2013 16:42

no drop here, was just a mm blip.

[stewart_25] 19/11/2013 15:44

big drop - ouch...

[bigspuds] 15/11/2013 17:44

Higher highs and higher lows. Classic.

[norbus] 08/11/2013 13:42

S

Navid always shamelessly talked this book. No reason to outperform unless they want to offload and perhaps Good does.

[christopher logsdon] 08/11/2013 13:39

Hi guys what's happening with the share prices going up a little why positive opinions please

[bigspuds] 07/11/2013 22:10

Never held 4 B4

[mhw28865] 07/11/2013 12:09

Would be more than happy if we can hold 4p today before the next leg up!!

[nw99] 07/11/2013 11:27

Statement looks like 9p is on the cards

[nw99] 07/11/2013 11:26

Looking good today peered thro 4p

[stewart_25] 04/11/2013 09:11

nw99 - is that a question or a statement?

[nw99] 02/11/2013 08:42

Shs mag chart view is it is going to 9p